Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential roles in supporting patients with Chronic Obstructive Pulmonary Disorder (COPD). The scientific rationale is based on omega-3’s anti-inflammatory properties, which may theoretically benefit the chronic airway inflammation characteristic of COPD. Some small clinical trials and observational studies have indicated that higher dietary intake or supplementation of omega-3 fatty acids may help reduce markers of airway inflammation, improve nutritional status, and possibly enhance quality of life in people with COPD. For example, a few studies have shown improvements in exercise capacity and reduced systemic inflammation in patients supplemented with omega-3s. However, the evidence remains limited and mixed; many studies have small sample sizes, are short in duration, or do not show significant clinical benefit in terms of lung function or exacerbation rates. Major clinical guidelines do not currently recommend routine omega-3 supplementation specifically for COPD management. In summary, while there is some scientific basis and preliminary data to support omega-3 use in COPD, robust, high-quality evidence is lacking, and its use remains adjunctive rather than established therapy.

More about omega-3 fatty acids
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)